Different approach in high-cardiovascular-risk women, compared to men:: a multidisciplinary study-Spain

被引:14
作者
Gutiérrez, PC
Bejarano, JML
Juanatey, JRG
Núñez, AG
Fernández, FJP
Sardá, AN
机构
[1] Univ Madrid, Hosp Gen Gregorio Maranon, Med Interna Serv, E-28007 Madrid, Spain
[2] Ctr Salud Villablanca, Area Sanitaria Numero Madrid 1, Madrid, Spain
[3] Univ Santiago, Hosp Clin, Serv Cardiol, La Coruna, Spain
[4] Univ Madrid, Hosp Gen Gregorio Maranon, Neurol Serv, Unidad Ictus, E-28007 Madrid, Spain
[5] Fdn Sarda Farriol, Inst Diabetol, Barcelona, Spain
来源
MEDICINA CLINICA | 2003年 / 120卷 / 12期
关键词
cardiovascular diseases; drug therapy; sex factors;
D O I
10.1016/S0025-7753(03)73736-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND AND OBJECTIVE: There is a broad range of cardiovascular high-risk patients, who might benefit from general and pharmacological interventions. The aim of the study was to evaluate the differences in the characteristics of CV risk in women with respect to men, and if there are differences in the treatment between men and women. PATIENTS AND METHOD: We collected the data from CV high-risk patients from Cardiology, Internal Medicine, Neurology, Endocrinology and Primary Care. We considered high-risk patients those with coronary artery disease, stroke, peripheral vascular disease, or diabetes plus one or more additional risk factor. Parameters recorded were age, gender, glucose, glycated haemoglobin, blood pressure, smoking habit, lipid profile, microalbuminuria, and pharmacological treatment. We performed an age-adjusted, multivariate analysis. RESULTS: Out of 5,207 patients, 1,307 were considered as high risk (56.1% men and 43.9% women). The median age was 67.3 years (66.1 y men, 68.8 y women). In the coronary heart disease group, women received less antiplatelet therapy (69.4% vs 80.4%; OR = 1.592) and less cholesterol-lowering agents (despite higher prevalence of hypercholesterolemia, 52.8% vs 39.1%). In diabetics patients with additional risk factors, women received less antiplatelet therapy (42.9% vs 36.6%, OR = 1.486) and lipid-lowering therapy (53.5% vs 41.4%), and more diuretics (41.4% vs 26.5%; OR = 0.588). CONCLUSIONS: There is a different profile of CV risk in women, with more diabetes and less smoking habit. In this study, a trend to less treat high-risk women with respect to high-risk men is observed.
引用
收藏
页码:451 / 455
页数:5
相关论文
共 12 条
[1]   Hormone replacement therapy in ischemic heart disease prevention in women. Arguments against [J].
Alonso, A ;
Ortigosa, J ;
Antorrena, I ;
Castro, A ;
Toquero, J ;
Arroyo, R ;
Conthe, P .
REVISTA ESPANOLA DE CARDIOLOGIA, 2001, 54 (04) :499-506
[2]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[3]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[4]  
Chalmers J, 1999, J HYPERTENS, V17, P151
[5]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[6]  
GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450
[7]   AN UPDATE ON CORONARY RISK-FACTORS [J].
KANNEL, WB ;
WILSON, PWF .
MEDICAL CLINICS OF NORTH AMERICA, 1995, 79 (05) :951-+
[8]   β-blockers for mild to moderate heart failure [J].
Krumholz, HM .
LANCET, 1999, 353 (9146) :2-3
[9]   Clinical effects of β-adrenergic blockade in chronic heart failure -: A meta-analysis of double-blind, placebo-controlled, randomized trials [J].
Lechat, P ;
Packer, M ;
Chalon, S ;
Cucherat, M ;
Arab, T ;
Boissel, JP .
CIRCULATION, 1998, 98 (12) :1184-1191
[10]  
LEWIS SJ, 1998, CARDIOL CLIN, V16, P1